Cancer is a complex disease whose outcome depends largely on the cross-talk between the
tumor and its microenvironment. Here, we review the evolution of the field of tumor …

Four proteasome subtypes are commonly present in mammalian tissues: standard
proteasomes, which contain the standard catalytic subunits β1, β2 and β5; …

Epithelial ovarian cancer (EOC) is a deadly disease with limited diagnostic biomarkers and
therapeutic targets. Here we conduct a comprehensive proteomic profiling of ovarian tissue …

Immunotherapy using immune checkpoint inhibitors (ICIs) induces durable responses in
many metastatic cancers. Metastatic uveal melanoma (mUM), typically occurring in the liver …

Hypoxia is an environmental stressor that is instigated by low oxygen availability. It fuels the
progression of solid tumors by driving tumor plasticity, heterogeneity, stemness and genomic …

The life of every organism is dependent on the fine-tuned mechanisms of protein synthesis
and breakdown. The degradation of most intracellular proteins is performed by the ubiquitin …

Accurate prognosis for cancer patients can provide critical information for optimizing
treatment plans and improving life quality. Combining omics data and demographic/clinical …

Proteasome dependency is a feature of many cancers that can be targeted by proteasome
inhibitors. For some cancer types, notably breast cancer and triple-negative breast cancer …

Cell-mediated immunity is driven by antigenic peptide presentation on major
histocompatibility complex (MHC) molecules. Specialized proteasome complexes called …

Motivation The goal of pharmacogenomics is to predict drug response in patients using their
single-or multi-omics data. A major challenge is that clinical data (ie patients) with drug …